Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

Published:2013-03-05 Issue:6 Volume:27 Page:1322-1327
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Pardanani A,Laborde R R,Lasho T L,Finke C,Begna K,Al-Kali A,Hogan W J,Litzow M R,Leontovich A,Kowalski M,Tefferi A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201371.pdf

Reference20 articles.

1. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 2012; 87: 25–33.

2. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392–397.

3. Tefferi A . How I treat myelofibrosis. Blood 2011; 117: 3494–3504.

4. Tefferi A . Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128–1138.

5. Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia 2011; 25: 1834–1839.

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies;Discover Oncology;2024-08-27

2. Momelotinib for the treatment of myelofibrosis;Blood;2024-08-15

3. Momelotinib: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2024-08

4. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients;Annals of Hematology;2024-07-29

5. Discovery of Two Highly Selective Structurally Orthogonal Chemical Probes for Activin Receptor-like Kinases 1 and 2;Journal of Medicinal Chemistry;2024-07-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3